Literature DB >> 21436708

Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations.

Limor Helpman1, Sarah E Ferguson, Melanie Mackean, Amira Rana, Lisa Le, Morven A Atkinson, Andrew Rogerson, Helen Mackay.   

Abstract

OBJECTIVE: The authors evaluated attitudes toward complementary and alternative medicine (CAM) use in 2 populations of women receiving chemotherapy for epithelial ovarian cancer (EOC).
METHODS: Women with EOC currently being treated with chemotherapy at 2 tertiary cancer centers, in Canada and the United Kingdom, completed a self-administered questionnaire on attitudes and perceptions of CAM and types of CAM used within the previous month.
RESULTS: One hundred ninety-two patients (94 from Canada, 98 from United Kingdom) completed the questionnaire. Overall, 85 women (44%) were identified as CAM users. Complementary and alternative medicine use was more common among Canadian women (52%) compared with women from the United Kingdom (37%), P = 0.02. Participants used 71 different types of CAM, the majority (61%) taking multiple CAM. The frequency of CAM use was the same in primary compared with recurrent disease. Eighty-nine percent of CAM users considered it important for their oncologist to be aware of CAM use. Canadian women, however, were less likely to inform their physician (Canada: 50%; United Kingdom: 81%), P = 0.02. Motivations for CAM use were the same in both populations including assist healing (60%), boost the immune system (57%), improve quality of life (48%), and relieve symptoms (45%). Thirteen percent thought CAM could cure cancer, whereas 17% thought it would prevent recurrence.
CONCLUSIONS: Complementary and alternative medicine use is common in women receiving chemotherapy for EOC. Increasingly, interactions between CAM and prescribed medication are being identified. Oncologists should be aware and actively inquire about CAM use. Although patterns of CAM use differed, the motivation for starting CAM was similar, highlighting the need to address supportive care in all patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436708     DOI: 10.1097/IGC.0b013e31820fa24a

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Correlation between an integrative oncology treatment program and survival in patients with advanced gynecological cancer.

Authors:  Yakir Segev; Ofer Lavie; Nili Stein; Walid Saliba; Noah Samuels; Eiman Shalabna; Orit Gressel Raz; Elad Schiff; Eran Ben-Arye
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.603

2.  Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy.

Authors:  Eran Ben-Arye; Noah Samuels; Elad Schiff; Orit Gressel Raz; Ilanit Shalom Sharabi; Ofer Lavie
Journal:  Support Care Cancer       Date:  2015-03-10       Impact factor: 3.603

3.  Polypharmacy in Patients with Ovarian Cancer.

Authors:  Sean Oldak; Stephanie Ioannou; Priyanka Kamath; Marilyn Huang; Sophia George; Brian Slomovitz; Matthew Schlumbrecht
Journal:  Oncologist       Date:  2019-04-05

4.  Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review.

Authors:  Mayuree Tangkiatkumjai; Helen Boardman; Dawn-Marie Walker
Journal:  BMC Complement Med Ther       Date:  2020-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.